Science News

A trial drug called APN01 or human recombinant soluble ACE2 (hrsACE2) can significantly block early stages of SARS-CoV-2 infections, according to a paper published in the journal Cell. “We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” said University of British Columbia’s Professor …